ArticleAntibiotics (Basel, Switzerland)2022
Active Surveillance for Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Seasonality and other factors influencing hospital acquisition of multi-drug-resistant Enterobacterales colonisation: a one-year cohort study - Botswana, 2022-2023.Infection prevention in practice · 2026Article
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Article
- Admission prognostic nutritional index improves risk stratification for the carbapenem-resistant phenotype in culture-positiveFrontiers in cellular and infection microbiology · 2026Article
- Intensive care unit-acquired rectal colonization and subsequent infections with carbapenem-resistant bacteria: a cross-sectional study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- The incidences and outcomes of acquiring multidrug-resistant Enterobacterales and enterococci colonization among hospitalized hematologic malignancy patients.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Epidemiological data on the acquisition of carbapenem-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Active Surveillance of Patients Colonized with CRE: A Single-Center Study Based on a Combined Molecular/Culture Protocol.Antibiotics (Basel, Switzerland) · 2024Article
- Development of a risk prediction model for subsequent infection after colonization with carbapenem-resistant Enterobacterales: a retrospective cohort study.Antimicrobial resistance and infection control · 2024Article
- Prevalence of intestinal colonization and nosocomial infection with carbapenem-resistantFrontiers in public health · 2023Article
- Carbapenem-Resistant Gram-Negative Bacteria Colonization in Immunocompromised and Critically Ill Pediatric Patients: Prevalence, Risk Factors, and Outcomes.Sage open pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal measures for preventing and controlling carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.